• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

热休克蛋白90介导γ干扰素诱导的对抗程序性死亡蛋白1免疫疗法的适应性抗性。

HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy.

作者信息

Liu Ke, Huang Jun, Liu Jiao, Li Changfeng, Kroemer Guido, Tang Daolin, Kang Rui

机构信息

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, China.

Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, China.

出版信息

Cancer Res. 2022 May 16;82(10):2003-2018. doi: 10.1158/0008-5472.CAN-21-3917.

DOI:10.1158/0008-5472.CAN-21-3917
PMID:35247909
Abstract

This study reveals an HSP90-centric, iron-modulated mechanism that confers immunosuppression, offering potential therapeutic targets for interfering with acquired resistance to the most prevalent anticancer immunotherapies.

摘要

这项研究揭示了一种以热休克蛋白90（HSP90）为中心、铁调节的免疫抑制机制，为干扰对最常见抗癌免疫疗法的获得性耐药提供了潜在的治疗靶点。

相似文献

1
HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy.热休克蛋白90介导γ干扰素诱导的对抗程序性死亡蛋白1免疫疗法的适应性抗性。
Cancer Res. 2022 May 16;82(10):2003-2018. doi: 10.1158/0008-5472.CAN-21-3917.
2
Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade.靶向 HSP90 可增强胰腺癌细胞对 PD-1 阻断的敏感性。
Oncoimmunology. 2022 Apr 25;11(1):2068488. doi: 10.1080/2162402X.2022.2068488. eCollection 2022.
3
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.联合阻断 IL6 和 PD-1/PD-L1 信号通路可消除肿瘤微环境中它们免疫抑制作用的相互调节。
Cancer Res. 2018 Sep 1;78(17):5011-5022. doi: 10.1158/0008-5472.CAN-18-0118. Epub 2018 Jul 2.
4
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.鉴定抗 PD-1 治疗耐药机制的“棘手难题”。
Clin Cancer Res. 2017 Jun 15;23(12):2921-2923. doi: 10.1158/1078-0432.CCR-17-0669. Epub 2017 May 3.
5
Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.麻疹病毒株联合抗程序性死亡蛋白1（PD-1）抗体阻断的免疫病毒疗法可增强胶质母细胞瘤治疗中的抗肿瘤活性。
Neuro Oncol. 2017 Apr 1;19(4):493-502. doi: 10.1093/neuonc/now179.
6
Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.全面深入了解在实体瘤中表达程序性死亡受体 1/程序性死亡配体 1 的免疫细胞的作用及调控机制。
Cancer Biol Med. 2020 Aug 15;17(3):626-639. doi: 10.20892/j.issn.2095-3941.2020.0112.
7
Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.在抗PD-1/PD-L1癌症免疫疗法中靶向调节性T细胞。
Scand J Immunol. 2022 Mar;95(3):e13129. doi: 10.1111/sji.13129. Epub 2022 Jan 12.
8
Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.靶向磷脂酰丝氨酸的抗体通过增强免疫激活和下调小鼠三阴性乳腺癌中由T细胞检查点抑制诱导的促癌因子，增强抗PD-1疗法的抗肿瘤活性。
Breast Cancer Res. 2016 May 11;18(1):50. doi: 10.1186/s13058-016-0708-2.
9
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.程序性死亡受体 1：癌症免疫治疗 100 多年后的治疗成功。
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8. doi: 10.1002/anie.201307906. Epub 2014 Jan 28.
10
IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells.γ干扰素通过上调肿瘤细胞上的细胞间黏附分子-1（ICAM-1）克服PD-L1/PD1对嵌合抗原受体T细胞（CAR-T）疗法的抑制作用。
Signal Transduct Target Ther. 2021 Jan 7;6(1):20. doi: 10.1038/s41392-020-00357-7.

引用本文的文献

1
Hsp90 and Isoform-Selective Inhibitors as Sensitizers for Cancer Immunotherapy.热休克蛋白90（Hsp90）及亚型选择性抑制剂作为癌症免疫治疗的增敏剂
Pharmaceuticals (Basel). 2025 Jul 10;18(7):1025. doi: 10.3390/ph18071025.
2
Proteins of the cancer cell secretome induce the protumoral microenvironment of diffuse intrinsic pontine glioma.癌细胞分泌组的蛋白质诱导弥漫性内在脑桥胶质瘤的促肿瘤微环境。
Neurooncol Adv. 2025 Jun 19;7(1):vdaf132. doi: 10.1093/noajnl/vdaf132. eCollection 2025 Jan-Dec.
3
A neuroimmune pathway drives bacterial infection.
一种神经免疫途径驱动细菌感染。
Sci Adv. 2025 May 2;11(18):eadr2226. doi: 10.1126/sciadv.adr2226.
4
CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies.靶向CD19的热休克蛋白90抑制剂纳米颗粒联合酪氨酸激酶抑制剂可减轻小鼠B细胞恶性肿瘤的肿瘤负担并增强T细胞免疫。
Theranostics. 2025 Feb 25;15(8):3589-3609. doi: 10.7150/thno.106758. eCollection 2025.
5
The aryl hydrocarbon receptor controls IFN-γ-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma.芳烃受体通过JAK/STAT途径调控肺腺癌中IFN-γ诱导的免疫检查点PD-L1和IDO。
J Immunol. 2025 Mar 3. doi: 10.1093/jimmun/vkae023.
6
NFE2L2 and SLC25A39 drive cuproptosis resistance through GSH metabolism.NFE2L2 和 SLC25A39 通过 GSH 代谢驱动铜死亡抗性。
Sci Rep. 2024 Nov 28;14(1):29579. doi: 10.1038/s41598-024-81317-x.
7
Cetylpyridinium chloride triggers paraptosis to suppress pancreatic tumor growth via the ERN1-MAP3K5-p38 pathway.十六烷基氯化吡啶通过ERN1-MAP3K5-p38途径触发副凋亡以抑制胰腺肿瘤生长。
iScience. 2024 Jul 26;27(8):110598. doi: 10.1016/j.isci.2024.110598. eCollection 2024 Aug 16.
8
The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma.芳烃受体通过JAK/STAT途径调控肺腺癌中IFNγ诱导的免疫检查点PD-L1和IDO。
bioRxiv. 2024 Aug 13:2024.08.12.607602. doi: 10.1101/2024.08.12.607602.
9
Heat shock protein 90α reduces CD8 T cell exhaustion in acute lung injury induced by lipopolysaccharide.热休克蛋白90α减轻脂多糖诱导的急性肺损伤中CD8 T细胞耗竭。
Cell Death Discov. 2024 Jun 13;10(1):283. doi: 10.1038/s41420-024-02046-8.
10
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity.多聚肌苷酸多聚胞苷酸的细胞质递送通过激活 Stat1-CCL2 介导的免疫来抑制胰腺癌进展，从而提高生存率。
J Immunother Cancer. 2023 Nov;11(11). doi: 10.1136/jitc-2023-007624.